Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

MASK study group

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR)control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores)was used to collect the data of daily visual analogue scale (VAS)scores for (1)overall allergic symptoms; (2)nasal, ocular, and asthma symptoms; (3)work; and (4)medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter)customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H 1 -antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control)treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H 1 -antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS)on a mobile phone had the potential to answer questions previously thought infeasible.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
Volume144
Issue number1
Pages (from-to)135-143.e6
ISSN0091-6749
DOIs
Publication statusPublished - 1. Jul 2019

Fingerprint

Hypersensitivity
Histamine Antagonists
Visual Analog Scale
Mobile Applications
Malus
Nose
Adrenal Cortex Hormones

Keywords

  • Allergic rhinitis
  • antihistamines
  • asthma
  • conjunctivitis
  • corticosteroids
  • MASK
  • mobile health
  • treatment

Cite this

@article{5e9ffde496b84c9580de874a17deb774,
title = "Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study",
abstract = "Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR)control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores)was used to collect the data of daily visual analogue scale (VAS)scores for (1)overall allergic symptoms; (2)nasal, ocular, and asthma symptoms; (3)work; and (4)medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter)customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H 1 -antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control)treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H 1 -antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS)on a mobile phone had the potential to answer questions previously thought infeasible.",
keywords = "Allergic rhinitis, antihistamines, asthma, conjunctivitis, corticosteroids, MASK, mobile health, treatment",
author = "Annabelle B{\'e}dard and Xavier Basaga{\~n}a and Anto, {Josep M.} and Judith Garcia-Aymerich and Philippe Devillier and Sylvie Arnavielhe and Anna Bedbrook and Onorato, {Gabrielle L.} and Wienczyslawa Czarlewski and Ruth Murray and Rute Almeida and Joao Fonseca and Elisio Costa and Joao Malva and Mario Morais-Almeida and Pereira, {Ana Margarida} and Ana Todo-Bom and Enrica Menditto and Cristiana Stellato and Ventura, {Maria Teresa} and Cruz, {Alvaro A.} and Rafa{\"e}l Stelmach and {da Silva}, Jane and D{\'e}sir{\'e}e Larenas-Linnemann and Fuentes-P{\'e}rez, {Jos{\'e} M.} and Huerta-Villalobos, {Yunuen R.} and Regina Emuzyte and Violeta Kvedariene and Arunas Valiulis and Piotr Kuna and Boleslaw Samolinski and Ludger Klimek and Ralph M{\"o}sges and Oliver Pfaar and Sara Shamai and Isabelle Annesi-Maesano and Isabelle Bosse and Pascal Demoly and Fontaine, {Jean Fran{\cc}ois} and Vicky Cardona and Joaquim Mullol and Antonio Valero and Roller-Wirnsberger, {Regina E.} and Tomazic, {Peter Valentin} and Chavannes, {Niels H.} and Fokkens, {Wytske J.} and Sietze Reitsma and Mike Bewick and Carsten Bindslev-Jensen and Esben Eller and {MASK study group}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.jaci.2019.01.053",
language = "English",
volume = "144",
pages = "135--143.e6",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby, Inc.",
number = "1",

}

Mobile technology offers novel insights into the control and treatment of allergic rhinitis : The MASK study. / MASK study group.

In: Journal of Allergy and Clinical Immunology, Vol. 144, No. 1, 01.07.2019, p. 135-143.e6.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Mobile technology offers novel insights into the control and treatment of allergic rhinitis

T2 - The MASK study

AU - Bédard, Annabelle

AU - Basagaña, Xavier

AU - Anto, Josep M.

AU - Garcia-Aymerich, Judith

AU - Devillier, Philippe

AU - Arnavielhe, Sylvie

AU - Bedbrook, Anna

AU - Onorato, Gabrielle L.

AU - Czarlewski, Wienczyslawa

AU - Murray, Ruth

AU - Almeida, Rute

AU - Fonseca, Joao

AU - Costa, Elisio

AU - Malva, Joao

AU - Morais-Almeida, Mario

AU - Pereira, Ana Margarida

AU - Todo-Bom, Ana

AU - Menditto, Enrica

AU - Stellato, Cristiana

AU - Ventura, Maria Teresa

AU - Cruz, Alvaro A.

AU - Stelmach, Rafaël

AU - da Silva, Jane

AU - Larenas-Linnemann, Désirée

AU - Fuentes-Pérez, José M.

AU - Huerta-Villalobos, Yunuen R.

AU - Emuzyte, Regina

AU - Kvedariene, Violeta

AU - Valiulis, Arunas

AU - Kuna, Piotr

AU - Samolinski, Boleslaw

AU - Klimek, Ludger

AU - Mösges, Ralph

AU - Pfaar, Oliver

AU - Shamai, Sara

AU - Annesi-Maesano, Isabelle

AU - Bosse, Isabelle

AU - Demoly, Pascal

AU - Fontaine, Jean François

AU - Cardona, Vicky

AU - Mullol, Joaquim

AU - Valero, Antonio

AU - Roller-Wirnsberger, Regina E.

AU - Tomazic, Peter Valentin

AU - Chavannes, Niels H.

AU - Fokkens, Wytske J.

AU - Reitsma, Sietze

AU - Bewick, Mike

AU - Bindslev-Jensen, Carsten

AU - Eller, Esben

AU - MASK study group

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR)control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores)was used to collect the data of daily visual analogue scale (VAS)scores for (1)overall allergic symptoms; (2)nasal, ocular, and asthma symptoms; (3)work; and (4)medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter)customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H 1 -antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control)treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H 1 -antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS)on a mobile phone had the potential to answer questions previously thought infeasible.

AB - Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR)control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores)was used to collect the data of daily visual analogue scale (VAS)scores for (1)overall allergic symptoms; (2)nasal, ocular, and asthma symptoms; (3)work; and (4)medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter)customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H 1 -antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control)treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H 1 -antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS)on a mobile phone had the potential to answer questions previously thought infeasible.

KW - Allergic rhinitis

KW - antihistamines

KW - asthma

KW - conjunctivitis

KW - corticosteroids

KW - MASK

KW - mobile health

KW - treatment

U2 - 10.1016/j.jaci.2019.01.053

DO - 10.1016/j.jaci.2019.01.053

M3 - Journal article

C2 - 30951790

AN - SCOPUS:85064769159

VL - 144

SP - 135-143.e6

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -